Most Clicked StoriesMore >


N.Y. attorney general sues over switch to new drug

PCMA SmartBrief | Sep 16, 2014

A federal antitrust lawsuit filed by New York State Attorney General Eric Schneiderman says Forest Laboratories is attempting to move patients to a newer version of its Alzheimer's drug to dodge generic competition. "A drug company manipulating vulnerable patients and forcing physicians to alter treatment plans unnecessarily, simply to protect corporate profits, is unethical and illegal," Schneiderman said. A representative of Actavis, which now owns Forest, said the company does not comment on pending lawsuits. New York Times (tiered subscription model), The (09/16)


N.Y. officials recommend prioritizing Sovaldi treatment

PCMA SmartBrief | Sep 19, 2014

Price of Gilead's next hep C drug to exceed Sovaldi's $84,000

PCMA SmartBrief | Sep 15, 2014

Lack of FDA regulation on biosimilars means less savings

PCMA SmartBrief | Sep 15, 2014

Insurer expands value-based formulary to combat drug prices

PCMA SmartBrief | Sep 17, 2014

OIG: Changing Medicare Part B pharmacy fees to Part D model could have saved $111M

PCMA SmartBrief | Sep 17, 2014

Tiered pharmacy benefit plans remain popular

PCMA SmartBrief | Sep 16, 2014

Drugmakers sow seeds of doubt about generics

PCMA SmartBrief | Sep 16, 2014

Group suggests ways for federal government to reduce opioid addiction

PCMA SmartBrief | Sep 17, 2014

Justice Department probes Ranbaxy Medicaid drug pricing

PCMA SmartBrief | Sep 18, 2014


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more